Telephone
61.3.7067.6940
Address
Level 3 100 Cubitt Street Cremorne, Victoria (VIC) 3121
Description
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.14 - 0.34
Trade Value (12mth)
AU$10,016.00
1 week
0%
1 month
-4.88%
YTD
-18.75%
1 year
-13.33%
All time high
4.60
EPS 3 yr Growth
-8.10%
EBITDA Margin
N/A
Operating Cashflow
-$10m
Free Cash Flow Return
-83.20%
ROIC
-81.40%
Interest Coverage
N/A
Quick Ratio
5.60
Shares on Issue (Fully Dilluted)
184m
HALO Sector
Healthcare
Next Company Report Date
01-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
24 April 25 |
Australian Federal Government Announces Funding of SMART CRC
×
Australian Federal Government Announces Funding of SMART CRC |
24 April 25 |
March 2025 Quarterly Activity Report and Appendix 4C
×
March 2025 Quarterly Activity Report and Appendix 4C |
14 April 25 |
Cynata Establishes New Scientific Advisory Board
×
Cynata Establishes New Scientific Advisory Board |
07 April 25 |
Promising Preclinical Heart Disease Data
×
Promising Preclinical Heart Disease Data |
01 April 25 |
Appendix 3Ys x 4
×
Appendix 3Ys x 4 |
18 March 25 |
Cynata Presenting at Advanced Therapies Congress
×
Cynata Presenting at Advanced Therapies Congress |
12 March 25 |
Cynata Participating in Euroz Hartleys Investor Conference
×
Cynata Participating in Euroz Hartleys Investor Conference |
27 February 25 |
Expiry of listed CYPOA Options
×
Expiry of listed CYPOA Options |
27 February 25 |
Appendix 4D & Half-Year Financial Statements
×
Appendix 4D & Half-Year Financial Statements |
20 February 25 |
Application for quotation of securities - CYP
×
Application for quotation of securities - CYP |
20 February 25 |
Appendix 3Y - Paul Wotton
×
Appendix 3Y - Paul Wotton |
06 February 25 |
Investor Webinar
×
Investor Webinar |
05 February 25 |
Publication comparing Cymerus MSCs to other MSCs
×
Publication comparing Cymerus MSCs to other MSCs |
04 February 25 |
Cynata to Present at Euroz Hartleys Healthcare Forum
×
Cynata to Present at Euroz Hartleys Healthcare Forum |
30 January 25 |
Quarterly Activity Report & Appendix 4C
×
Quarterly Activity Report & Appendix 4C |
23 January 25 |
Application for quotation of securities - CYP
×
Application for quotation of securities - CYP |
23 January 25 |
Cleansing Notice
×
Cleansing Notice |
23 January 25 |
Appendix 3Y x 5
×
Appendix 3Y x 5 |
21 January 25 |
Results of Meeting
×
Results of Meeting |
13 January 25 |
Cynata to Present at Biotech Showcase
×
Cynata to Present at Biotech Showcase |
31 December 24 |
Change in substantial holding - Phillip Asset Management
×
Change in substantial holding - Phillip Asset Management |
20 December 24 |
Letter to Shareholders, Notice of EGM & Proxy Form
×
Letter to Shareholders, Notice of EGM & Proxy Form |
16 December 24 |
Application for quotation of securities - CYP
×
Application for quotation of securities - CYP |
16 December 24 |
Cleansing Notice
×
Cleansing Notice |
12 December 24 |
First Kidney Transplant Trial Patient Treated
×
First Kidney Transplant Trial Patient Treated |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.